These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18810795)

  • 1. Contaminated heparin.
    Kakkar AK; Bonnefoi M
    N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
    [No Abstract]   [Full Text] [Related]  

  • 2. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
    Lindahl U
    Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
    [No Abstract]   [Full Text] [Related]  

  • 3. Contaminated heparin.
    Greinacher A; Warkentin TE
    N Engl J Med; 2008 Sep; 359(12):1291-2; author reply 1293. PubMed ID: 18799565
    [No Abstract]   [Full Text] [Related]  

  • 4. Contaminated heparin associated with adverse clinical events and activation of the contact system.
    Kishimoto TK; Viswanathan K; Ganguly T; Elankumaran S; Smith S; Pelzer K; Lansing JC; Sriranganathan N; Zhao G; Galcheva-Gargova Z; Al-Hakim A; Bailey GS; Fraser B; Roy S; Rogers-Cotrone T; Buhse L; Whary M; Fox J; Nasr M; Dal Pan GJ; Shriver Z; Langer RS; Venkataraman G; Austen KF; Woodcock J; Sasisekharan R
    N Engl J Med; 2008 Jun; 358(23):2457-67. PubMed ID: 18434646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin comes clean.
    Schwartz LB
    N Engl J Med; 2008 Jun; 358(23):2505-9. PubMed ID: 18525048
    [No Abstract]   [Full Text] [Related]  

  • 6. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contaminants in heparins continue to be unfolded.
    Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL
    Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contaminants in heparins: are all facts known?
    Fareed J; Hoppensteadt DA; Ramacciotti E; Hull RD
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):242-3. PubMed ID: 20547552
    [No Abstract]   [Full Text] [Related]  

  • 11. Contaminated heparin-affected patient plasmas are associated with activated contact systems.
    Yi Qian ; Jing Pan ; Xiaodong Zhou ; Weiser P; Hong Lu ; Beck AM; Shih FF; Lijuan Zhang
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):261-5. PubMed ID: 20547554
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
    Bairstow S; McKee J; Nordhaus M; Johnson R
    Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anaphylactoid reactions associated with contaminated heparin from China].
    Montpas N; Désormeaux A; Keire D; Adam A
    Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
    Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 16. Contaminants in heparin.
    Hull R; Walenga J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):125. PubMed ID: 21406418
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
    Warkentin TE; Greinacher A
    Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins.
    Martin M; Ott H; Merk HF; Sachs B
    Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contaminated heparin preparations, severe adverse events and the contact system.
    Ramacciotti E; Wahi R; Messmore HL
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
    [No Abstract]   [Full Text] [Related]  

  • 20. Prothrombin time for detection of contaminated heparins.
    Alban S; Lühn S
    N Engl J Med; 2008 Dec; 359(25):2732-4. PubMed ID: 19052118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.